The potential for artificial intelligence in precision medicine is big, according to conclusions of a new study by the New York Genome Center and IBM. The results, published in the July 11 issue of Neurology Genetics, a journal of the American Academy of Neurology, showed that researchers at the New York Genome Center, Rockefeller University and other institutions – along with IBM – verified the potential of IBM Watson for Genomics to analyze complex genomic data from state-of-the-art DNA sequencing of whole genomes. "This study documents the strong potential of Watson for Genomics to help clinicians scale precision oncology more broadly," Vanessa Michelini, Watson for Genomics Innovation Leader for IBM Watson Health, said in a statement. "Clinical and research leaders in cancer genomics are making tremendous progress towards bringing precision medicine to cancer patients, but genomic data interpretation is a significant obstacle, and that's where Watson can help." The proof of concept study compared multiple techniques used to analyze genomic data from a glioblastoma patient's tumor cells and normal healthy cells, putting to work a beta version of Watson for Genomics technology to help interpret whole genome sequencing data for one patient.
Rapid advancements in the field of artificial intelligence (AI) are uniquely poised to transform entire occupations and industries, changing the way work will be done in the future. It is imperative to understand the extent and nature of the changes so that we can prepare today for the jobs of tomorrow. New empirical work from the MIT-IBM Watson AI Lab uncovers how jobs will transform as AI and new technologies continue to scale across business and industries. We created a novel dataset using machine learning techniques on 170 million U.S. job postings. The dataset and research, The Future of Work: How New Technologies Are Transforming Tasks, allow us to extract key insights into how AI is shaping the future of work.
AI may not be able to lead us just yet, but it can judge how well we lead. New findings suggest Apple's CEO, Tim Cook, may just be Silicon Valley's "most imaginative" leader, reported CNBC, citing data from job search firm Paysa. It examined their "speeches, essays, books, transcripts of interviews and other forms of communication" to generate a Personality Insights report. Cook emerged as the industry's "most imaginative" leader, followed by Amazon's Jeff Bezos. Advances in AI mean IBM's Watson can do more than just read your personality.
In 2014, IBM opened swanky new headquarters for its artificial intelligence division, known as IBM Watson. Inside the glassy tower in lower Manhattan, IBMers can bring prospective clients and visiting journalists into the "immersion room," which resembles a miniature planetarium. There, in the darkened space, visitors sit on swiveling stools while fancy graphics flash around the curved screens covering the walls. It's the closest you can get, IBMers sometimes say, to being inside Watson's electronic brain. One dazzling 2014 demonstration of Watson's brainpower showed off its potential to transform medicine using AI--a goal that IBM CEO Virginia Rometty often calls the company's moon shot. In the demo, Watson took a bizarre collection of patient symptoms and came up with a list of possible diagnoses, each annotated with Watson's confidence level and links to supporting medical literature. Within the comfortable confines of the dome, Watson never failed to impress: Its memory banks held knowledge of every rare disease, and its processors weren't susceptible to the kind of cognitive bias that can throw off doctors. It could crack a tough case in mere seconds. If Watson could bring that instant expertise to hospitals and clinics all around the world, it seemed possible that the AI could reduce diagnosis errors, optimize treatments, and even alleviate doctor shortages--not by replacing doctors but by helping them do their jobs faster and better.
IBM's (NYSE:IBM) famed Watson artificial intelligence platform will be put to use to help match cancer patients with clinical trials. The Armonk, N.Y.-based technology giant said Froedtert & the Medical College of Wisconsin Network will adopt the Watson technology for this purpose in a project set to begin this fall. Froedtert/MCW Cancer Network are among the 1st cancer programs nationally to use the technology, according to IBM. Doctors typically try to match patients to genetically ideal clinical trials that are also the most relevant in the development spectrum. This can be a long process on multiple levels, involving reviews by clinical coordinators who manually sort through patient records and conditions.